Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males

Next Previous
X
Search
Trial Profile

Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PXS-5338K (Primary)
  • Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
  • Focus Adverse reactions
  • Sponsors Pharmaxis; Syntara Limited

    • Most Recent Events

    • 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
    • 11 Oct 2018 Results of this trial for first Lysyl Oxidase Like 2 (LOXL2) inhibitor (PXS-5338K) presented in an Arix Bioscience media release.
    • 24 Sep 2018 The actual date of last participant enrollment is 5/6/2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top